The Top Ten Tweets of 2015 (So Far)


Applied Clinical Trials

 This following list comprises all of our most popular Tweets from 2015. Find out what made the cut and read more about trending topics regarding Clinical Trials.Follow @Clin_Trials for more information!   

This following list comprises all of our most popular Tweets from 2015. Find out what made the cut and read more about trending topics regarding Clinical Trials.

Follow @Clin_Trials for more information!





Patient adherence is an emerging topic and a matter of concern in clinical research. Patient adherence can apply to several different clinical trial facets which may include adherence to study procedures, study visit compliance, medications, and adverse event reporting to name a few.

Read the full article here.




Europital announces the official launching and availability of its electronic platform Penthu® for managing medical issues in clinical trials. Penthu® is an innovative and intuitive platform that drives performance, knowledge and efficiencies in clinical trials.


Read the full article here.




Optimizing study protocols and improving data quality have been notable areas of focus in the biopharmaceutical industry; the total number of endpoints in a typical Phase III protocol increased from 7 to 13, the number of eligibility criteria rose from 31 to 50, and the number of investigative sites increased from 124 to 196, yet the total number of patients randomized declined from 729 to 597 from 2002-2012, respectively.


Read the full article here.






ResearchKit is Apple’s foray into clinical research based on the backbone of its HealthKit, released  in June 2014, which offered the ability for health and fitness apps to communicate with each other. mHealth News reported Apple CEO Tim Cook said, “As we worked on HealthKit, we came across an even broader impact that iPhone could make, and that is on medical research.”

Read the full article here.




The SiteCloud platform is the same technology used by TransCelerate’s Investigator Registry and the Investigator Databank. Using  a universal identifier within the platform allows INC to match data from numerous disparate sources.


Read the full release here.




After decades of promise, we have begun to realize the fruit of “-omics” technology. Recent advances in proteomics, genomics and metabolomics have enabled us to understand the molecular basis of disease at both the diagnostic and treatment levels. Equally important, a growing suite of biomarkers now provides predictive value for diagnosis, disease progression and cure/remission.


Read the full article here.




Learn more here.




Satisfaction surveys provide clinicians valuable insight into quality-of-care metrics. However, in order for satisfaction surveys to be most useful and yield meaningful results that can improve patient outcomes and well being, the responses must be truthful and accurately reflect the respondent’s inherent satisfaction. To achieve this goal, it is important that the survey be constructed and administered properly.


Read the full article here.




Drug development has never before been so difficult, time consuming and expensive. Accuracy in clinical trials, therefore, is a priority. However, suboptimal adherence is prevalent in ambulatory trials, in which outpatients are responsible for taking the drug according to the protocol-specified dosing regimen.


Read the full article here.




That intriguing question raises important issues about how widespread patient sharing of information over the Internet can both support and undermine efforts to obtain meaningful results from biopharmaceutical research studies. Disease group chat rooms, instant messaging and Facebook pages can help recruit patients to clinical trials and make them feel part of a community making an important contribution to health and science.


Read the full article here.

Related Content
© 2024 MJH Life Sciences

All rights reserved.